



TJW

PATENTS
Attorney Docket No. TNA-005.04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
Jin-An Jao et al.)	
Application No:)	Art Unit: 1646
10/618,338)	
Filed:)	Confirmation No.: 8452
July 11, 2003)	
For:)	Examiner: Not yet known
ANTIBODIES FOR INHIBITING)	
BLOOD COAGULATION AND)	
METHODS OF USE THEREOF)	

CERTIFICATE OF MAILING/TRANSMISSION

I hereby certify that the correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 30, 2005.

Katelyn Nelson

Katelyn Nelson

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION-DISCLOSURE STATEMENT

Applicants hereby bring to the Examiner's attention the references listed on the accompanying form PTO-1449. Pursuant to 37 C.F.R. § 1.98 (2)(i), Applicants have not enclosed copies of the cited U.S. patents or publications. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.


Applicants have listed dates of publication on the attached PTO-1449 for the cited documents based on information presently available to the undersigned. However, the listed publication dates should not be construed that the information in the cited documents was actually published or otherwise publicly available on the date indicated.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that each or all of the listed documents are material or constitute "prior art." Further, if the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Moreover, the Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Under 37 C.F.R. § 1.97 (b)(3), this Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits; therefore, no fee is believed to be due in connection with this submission. However, the Commissioner is authorized to charge any deficiencies or credit any overpayment to our **Deposit Account, No. 06-1448, Reference TNA-005.04.**

Respectfully submitted,

Date: September 30, 2005
Customer No: 25181
Patent Group
Foley Hoag, LLP
155 Seaport Blvd.
Boston, MA 02210-2600


Beth E. Arnold, Reg. No. 35,430
Attorney for Applicants
Tel. No. (617) 832-1294
Fax. No. (617) 832-7000

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**
(Use several sheets if necessary)
Docket Number (Optional)
TNA-005.04Applicant
Jin-An Jao et al.Filing Date
July 11, 2003Application Number
10/618,338Group Art Unit
1646
U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BG 5,693,762	12/02/97	Queen et al.			
	BH 5,869,046	02/09/99	Presta et al.			
	BI 5,986,065	11/16/99	Wong et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
	BK WO 94/05328	03/17/94	PCT				
	BJ WO 96/40921	12/19/96	PCT				
	BL WO 99/43713	09/02/99	PCT				
	BM WO 01/70984	09/27/01	PCT				
	BN 1-503438	1989	Japan				X

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

	BO	Carson et al., "An Inhibitory Monoclonal Antibody Against Human Tissue Factor," Blood, 70(2):490-493 (1987)
	BP	Caulfield, M.J. et al. "A pathogenic monoclonal antibody, G8, is characteristic of antierythrocyte autoantibodies from Coombs'-positive NZB mice," J. Immunol. 148(7):2068-2073 (1992)
	BQ	Database EMBL: MMG8LC, Accession #X60425, October 21, 1991 Description "G8 (ANTI-MRBC) V(L), J(L)" XP-002305737
	BR	Presta et al., "Generation of a Humanized, High Affinity Anti-Tissue Factor Antibody for Use as a Novel Antithrombotic Therapeutic," Thromb Haemost 85:379-89 (2001)
	BS	Wen Jinghai et al. "Antibody-dependent cellular cytotoxicity and antibody dependent cellular phagocytosis of breast cancer cells mediated by anti-tissue factor monoclonal antibodies," FASEB Journal, 15(5):A1198 (2001) Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biol; Orlando, Florida, March 31-April 4, 2001 Abstract